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Abstract
Background: The aim of this study was to identify clinical risk factors for antimicrobial resistances and multidrug
resistance (MDR) in urinary tract infections (UTI) in an emergency department in order to improve empirical therapy.
Methods: UTI cases from an emergency department (ED) during January 2013 and June 2015 were analyzed. Differences
between patients with and without resistances towards Ciprofloxacin, Piperacillin with Tazobactam (Pip/taz), Gentamicin,
Cefuroxime, Cefpodoxime and Ceftazidime were analyzed with Fisher’s exact tests. Results were used to identify risk
factors with logistic regression modelling. Susceptibility rates were analyzed in relation to risk factors.
Results: One hundred thirty-seven of four hundred sixty-nine patients who met the criteria of UTI had a positive urine
culture. An MDR pathogen was found in 36.5% of these. Overall susceptibility was less than 85% for standard
antimicrobial agents. Logistic regression identified residence in nursing homes, male gender, hospitalization within the
last 30 days, renal transplantation, antibiotic treatment within the last 30 days, indwelling urinary catheter and recurrent
UTI as risk factors for MDR or any of these resistances. For patients with no risk factors Ciprofloxacin had 90%, Pip/taz 88%,
Gentamicin 95%, Cefuroxime 98%, Cefpodoxime 98% and Ceftazidime 100% susceptibility. For patients with 1 risk factor
Ciprofloxacin had 80%, Pip/taz 80%, Gentamicin 88%, Cefuroxime 78%, Cefpodoxime 78% and Ceftazidime 83%
susceptibility. For 2 or more risk factors Ciprofloxacin drops its susceptibility to 52%, Cefuroxime to 54% and Cefpodoxime
to 61%. Pip/taz, Gentamicin and Ceftazidime remain at 75% and 77%, respectively.
Conclusions: We identified several risk factors for resistances and MDR in UTI. Susceptibility towards antimicrobials
depends on these risk factors. With no risk factor cephalosporins seem to be the best choice for empiric therapy, but in
patients with risk factors the beta-lactam penicillin Piperacillin with Tazobactam is an equal or better choice compared to
fluoroquinolones, cephalosporins or gentamicin. This study highlights the importance of monitoring local resistance rates
and its risk factors in order to improve empiric therapy in a local environment.
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Background
Urinary tract infections (UTI) are among the most com-
mon bacterial infections worldwide. Their therapy is be-
coming more challenging as resistance rates for standard
antibiotics are increasing [1]. The increase of antibiotic
resistances and multi-drug resistance (MDR) pathogens
in UTI is associated with higher rates of inadequate em-
pirical therapy due to impaired antibiotic coverage [2].
Therefore, early identification of patients at risk for
antibiotic resistances is an important aspect for effective
treatment. Preceding studies identified a variety of risk
factors mainly for treatment failure for either fluoroqui-
nolones or trimethoprim-sulfamethaxol or for UTI with
MDR pathogens. Rarely did they quantify the impact of
risk factors on overall susceptibility to standard empir-
ical therapy choices [3–8].
The goal of our study was to identify risk factors asso-
ciated with several antibiotic resistances and MDR
pathogens in patients presenting with UTI, mainly py-
elonephritis or urosepsis, to the emergency department
(ED) of a German academic tertiary care facility. We
hypothesized that the identification of risk factors will
improve empiric antibiotic therapy in the ED.
Methods
The study was retrospectively conducted with anon-
ymized patient data from the ED of an academic tertiary
care facility. The local ethics committee of the Medical
Faculty of Mannheim has approved the study. Cases
were eligible for the study, if they were diagnosed with
lower or upper UTI in the ED between January 2013
and June 2015. Lower UTI was defined as dysuria,
pollakisuria or positive leucocyte and nitrite in urine in
patients with reduced vigilance. Upper UTI was defined
by additional flank pain, fever, positive systemic inflam-
mation serum parameters or perinephritic abscess in
sonography [9].
Patient information included the following: demo-
graphic parameters (gender, age, residence), laboratory
analysis (C-reactive protein, leucocyte count, serum
creatinine and glomerular filtration rate (GFR) calculated
after Modification of Diet in Renal Disease formula),
physical condition at admission (signs of exsiccosis,
symptoms at presentation), urine analysis (isolated
pathogen, pathogen count, antimicrobial susceptibility
testing), comorbidities (diabetes mellitus, indwelling
urinary catheter, renal transplantation, dialysis), pre-ED
antibiotic treatment within the last 30 days, prior
hospitalization within the last 30 days and UTI within
the last 12 months.
We assessed patients with clinical symptoms consist-
ent with UTI and positive urine culture. A positive result
was defined as colony-forming unit > 104/ml for cath-
eter- or midstream-urine and > 103/ml for single-use-
catheter. Urine cultures labeled by the microbiology
laboratory as “contamination” or “mixed flora” were
excluded.
MDR and extensively drug-resistant (XDR) pathogens
were defined according to the European Centre for
Disease Prevention and Control [10]: MDR describes
pathogens non-susceptible to at least one agent in three
or more antimicrobial categories. XDR describes patho-
gens fully susceptibly to only two or less antimicrobial
categories.
Data were grouped by presence of antibiotic resis-
tances towards antimicrobial substances frequently used
in the treatment of UTIs. We chose Ciprofloxacin (Cip),
Ceftazidime, Cefpodoxime, Gentamicin, Piperacillin with
Tazobactam (Pip/taz) and Cefuroxime for further ana-
lysis. Risk factors for carbapenem non-susceptibility
were not analyzed as overall non-susceptibility was low.
Differences in parameters between groups with or with-
out resistances towards a certain antibiotic were tested
for significance with Fisher’s exact testing.
Logistic regression was then performed to identify risk
factors for resistances toward antimicrobial substances
mainly used in upper UTI treatment, MDR pathogens
and pathogens simultaneously resistant to Ciprofloxacin,
Pip/taz and Ceftazidime (sCPC). The results were pre-
sented with odds ratios and their corresponding 95%
confidence interval (CI). The area under the curve
(AUC)/c-statistic of a Receiver Operating Characteristic
(ROC) analysis was calculated and used to estimate the
accuracy of fit of our model. The AUC measures the ac-
curacy for the prediction with an AUC = 1.0 representing
perfect prediction.
Susceptibility data were calculated for Ciprofloxacin,
Ceftazidime, Cefpodoxime, Cefuroxime, Pip/taz, Genta-
micin and Imipenem. Susceptibility was analyzed for the
whole patient collective as well as subgroups defined by
the number of risk factors present.
All analyses were performed using SAS system for
Microsoft version 9.4. (SAS Institute Inc., Cary, North
Carolina, USA).
Results
Demographics and pathogen distribution
Between January 2013 and June 2015, the ED treated
and admitted 469 cases, who met the criteria of UTI. In
184 cases no urine culture was performed, 143 urine
cultures had a negative result or were contaminated. In
5 cases the initial diagnosis of upper UTI could not be
confirmed during hospital stay. One hundred thirty-
seven had an uncontaminated urine culture with a posi-
tive result, of which 130 (94.9%) met the criteria for
upper UTI. These patients were mostly female (80/137,
58.4%) with a median age of 76.0y (average 72.1y, range
17-97y). Twenty-seven patients resided in nursing
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homes (19.7%), 22 had indwelling urinary catheters
(16.1%), 33 were admitted to a hospital within the last
30 days (24.1%) and 20 received antibiotic treatment
within 30 days prior to their ED visit (14.6%; Table 1). In
all patients, symptoms of infection started before admis-
sion, thus presenting either community acquired UTI or
community-onset healthcare-associated urinary tract
infections.
Of 137 urine cultures, main pathogens were Escherichia
coli in 64.2% (n = 88), Klebsiella pneumoniae or oxytoca in
12.4% (n = 17), Enterococci spp. in 5.1% (n = 7), Pseudo-
monas aeruginosa in 5.1% (n = 7), Proteus mirabilis in
4.4% (n = 6), Staphylococcus aureus in 3.7% (n = 5) and
Citrobacter spp. in 2.2% (n = 3) of cases.
All samples were tested for susceptibility towards Cip-
rofloxacin (Cip), Piperacillin with Tazobactam (Pip/taz),
Gentamicin, Cefuroxime, Cefpodoxime and Ceftazidime
and Imipenem. In our study 36.5% (50/137) of patho-
gens can be classified as MDR. Most MDR pathogens
were E. coli (62.7%) followed by K. pneumonia (13.7%).
XDR pathogens were detected in 3.7% (5/137). Non-
susceptibility to all three antibiotics Ciprofloxacin, Pip/
taz and Ceftazidime (sCPC), which are commonly used
for the empiric therapy of severe pyelonephritis, was
detected in 5.1% (7/137).
Risk factors for antibiotic non-susceptibility
An analysis of patient characteristics revealed residence
in nursing homes, prior hospitalization within 30 days,
usage of antibiotics 30 days prior to admission, indwell-
ing urinary catheter, recent or recurrent UTI, gender,
renal transplantation and serum leucocyte count > 12.0/
nl as significantly different between patients with and
without non-susceptibility (p < 0.05 in Fisher’s exact
testing; data not shown). Logistic regression was per-
formed to allocate risk factors to non-susceptibility to a
certain antibiotic, MDR pathogen or to simultaneous
non-susceptibility towards Ciprofloxacin, Pip/taz and
Ceftazidime (sCPC). Seven factors showed a significant
association (Table 2). ROC analysis yielded AUC values
of 0.650 to 0.868 indicating an overall good fit of our
models.
Antimicrobial susceptibility in relation to risk factors
Overall susceptibility for commonly used antibiotics in
upper UTI was low with 71.5% for Cip, 80.3% for Pip/taz,
84.6% for Gentamicin, 73.7% for Cefuroxime, 76.6% for
Cefpodoxime and 85.4% for Ceftazidime (Table 3). Ampi-
cillin with Sulbactam had an overall susceptibility of 54.7%
and was therefore not further analyzed. Only Imipenem
showed an acceptable susceptibility rate of 96.4%.
In order to recommend non-carbapenem antibiotics
for the treatment of upper UTI in the ED we analyzed
susceptibility rates by previously identified risk factors.
Without a risk factor present all antibiotics had a
susceptibility rate of around 90% and above (n = 41). If
one of seven risk factors were present, susceptibility for
all antibiotics except for Imipenem dropped to around
80% (n = 40) (Fig. 1). For 2 or more risk factors Cip,
Cefuroxime and Cefpodoxime dropped to 60% and
below, while Pip/taz, Gentamicin and Ceftazidime
remained at around 75% (n = 56). In this case, the
Table 1 Demographic parameters of patients with a positive
urine culture
All (n = 137)
n Percentage
Age
Mean 72.1 (18.2)
< 65 years 30 (21.9)
65–80 years 55 (40.1)
> 80 years 52 (38.0)
Gender
female 80 (58.4)
Nursing home
yes 27 (19.7)
Hospitalization within 30 days
yes 33 (24.1)
Antibiotic treatment within 30 days
yes 20 (14.6)
Recent UTI
yes 30 (21.9)
Diabetes
yes 47 (34.3)
Renal transplantation
yes 4 (2.9)
Indwelling urinary catheter
yes 22 (16.1)
Hemodialysis
yes 4 (2.9)
Exsiccosis
yes 40 (29.2)
Fever
yes 50 (36.5)
leucocyte count
> 12 /nl 56 (40.9)
GFR (from serum creatinine)
< 15 ml/min 5 (3.7)
< 60 ml/min 79 (57.7)
C-reactive protein
> 100 mg/l 64 (46.7)
GFR glomerular filtration rate
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susceptibility rate of Imipenem also dropped to 91.1%
(Table 3). Whereas cephalosporins and Gentamicin seem
to be preferable in patients with no risk factors in regard
to susceptibility, their susceptibility rates were similar to
Pip/taz and Cip in patients with one risk factor. Interest-
ingly, Pip/taz, Gentamicin and Ceftazidime kept their
susceptibility rate relatively stable with more risk factors
whereas Cip, Cefuroxime and Cefpodoxime dropped
their susceptibility rates to a greater extent.
The logistic regression modelling showed that not all
antibiotics share the same risk factor profile (Table 2),
therefore sub analysis was performed. In our population,
patients, who have been admitted to a hospital within the
previous 30 days and resided in a nursing home (n = 9),
showed a much better susceptibility rate for cephalospo-
rins (77.8%) compared to Gentamicin (55.6%), Pip/taz
(33%) or Ciprofloxacin (11%). In contrast, patients with
antibiotic therapy 30 days prior to admission (n = 20) had
a high susceptibility rate for Pip/taz 95% compared to
Gentamicin (80.0%), Cefuroxime 45.0%, Cefpodoxime
50.0%, Ceftazidime 75.0% and Ciprofloxacin 60.0%. Our
data suggest that patients with previous antibiotic therapy
may be better treated with Pip/taz as empiric therapy.
Therapy algorithm
From our data we concluded for our ED that for patients
without a risk factor a cephalosporin-based empiric
treatment or Gentamicin has the lowest rate of non-
susceptibility (Fig. 2). However, with one or more risk
factors Pip/taz is equal to or better as cephalosporins or
Ciprofloxacin, particularly in case of prior antibiotic
therapy. An exception could be patients residing in a
nursing home and who have been admitted to a hospital
Table 2 Logistic regression modelling presented as Odds Ratio with 95% confidence interval and corresponding AUC
Target Nursing home
residence
Hospitalization
within 30 days
Male sex Renal
transplantation
Indwelling urinary
catheter
Use of antibiotics
within 30 days
Recurrent
UTI
AUC
Pip/taz n.s. 3.7
(1.4–9.5)**
n.s. 15.4
(1.4–172.1)*
n.s. n.s. n.s. 0.699
Ciprofloxacin n.s. 4.4
(1.8–10.6)**
n.s. n.s. 5.2
(1.8–14.7)**
n.s. n.s. 0.749
Gentamicin n.s. n.s. n.s. 24.8
(2.4–257.2)**
3.1
(1.0–9.4)*
n.s. n.s. 0.650
Cefuroxime n.s. n.s. 7.3
(2.9–18.5)***
n.s. n.s. 5.7
(1.8–17.7)**
n.s. 0.792
Cefpodoxime n.s. n.s. 6.5
(2.5–17.0)***
n.s. n.s. 5.3
(1.7–16.3)**
n.s. 0.788
Ceftazidime n.s. n.s. 3.7
(1.3–10.6)*
16.4
(1..5–182.1)*
n.s. n.s. n.s. 0.715
MDR n.s. 3.6
(1.5–8.5)**
n.s. n.s. n.s. n.s. 4.0
(1.7–9.8)**
0.707
sCPC 22.8
(3.4–151.2)**
n.s. 9.5
(1.4–62.5)*
n.s. n.s. n.s. n.s. 0.868
* p < 0,05; ** P < 0,01; ***p < 0,001; n.s. not significant, UTI urinary tract infection, AUC Area under the curve, Pip/taz Piperacillin/Tazobactam, MDR multidrug
resistance, sCPC simultaneous non-susceptibility for Pip/taz, Ciprofloxacin and Ceftazidime
Table 3 Susceptibility in % in relationship to number of risk
factors (RF)
Overall 0 RF 1 RF > = 2 RF
(n = 137) (n = 41) (n = 40) (n = 56)
Ciprofloxacin 71.5% 90.2% 80.0% 51.8%
Pip/taz 80.3% 87.8% 80.0% 75.0%
Gentamicin 84.7% 95.1% 87.5% 75.0%
Ceftazidime 85.4% 100% 82.5% 76.8%
Cefpodoxime 76.6% 97.6% 77.5% 60.7%
Cefuroxime 73.7% 97.6% 77.5% 53.7%
Imipenem 96.4% 100% 100% 91.1%
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Fig. 1 Susceptibility in relationship to number of risk factors -
Susceptibility in % for Piperacillin/Tazobactam (red), Ceftazidime
(grey), Cefpodoxime (violet), Cefuroxime (green), Ciprofloxacin
(yellow), Imipinem (light blue) and Gentamicin (dark blue) are
plotted for 0, 1 and 2 and more (2+) risk factors present
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in the previous 30 days. They could benefit from Cefpo-
doxime or Cefuroxime as an initial treatment choice.
In our study, only 80 of 124 patients (64.5%) received
an empiric therapy that showed susceptibility to its caus-
ing pathogen in urine culture testing. Thirty-three
patients received a cephalosporin as empiric therapy, 10
Pip/taz, 15 Ciprofloxacin, but 54 Ampicillin/Sulbactam.
An empiric therapy based on common guidelines for
upper UTI such as ciprofloxacin would have an overall
susceptibility of 71, 5% (Table 3). Following our risk fac-
tor based decision algorithm, 86.1% (107/124) would
have received a susceptible antibiotic treatment. In this
algorithm, patients with one or more risk factors would
have been treated with Pip/taz except for patients, who
had been admitted to the hospital within the last 30 days
prior to admission and reside in a nursing home, which
would have received a cephalosporine. All patients with-
out a risk factor would have received Cefpodoxime or
Cefuroxime as first line therapy (Fig. 2).
Discussion
With the increase of microbial resistance, empiric ther-
apy recommendations without taking local resistance
data into account can lead to inferior treatment results.
In our data set treating patients with upper UTI per
current treatment guidelines would have led to incorrect
antibiotic coverage in nearly 30% of cases [9]. Early iden-
tification of patients at risk of antibiotic resistances and
thus therapy failure is an important part of an effective
empiric therapy.
In the past risk factors for extended-spectrum-
betalactamase producing bacteria in non-hospitalized
patients with UTI have for example been identified as re-
cent hospitalizations within 3 months, previous antibiotic
usage, age > 60 years, diabetes mellitus, male gender, pre-
vious UTI with Klebsiella spp., residence in long-term care
facilities, indwelling urinary catheters, recurrent UTIs and
previous fluoroquinolone use [11, 12]. Analogous results
were obtained for fluoroquinolones [3, 6–8, 13]. In a
similar setting to ours, Faine et al. evaluated risk factors
for MDR pathogens in UTI in the United States [14].
Their overall MDR rate was only 6.7% in contrast to
36.5% in our population. Faine et al. used a more restrict-
ive MDR definition, which may explains the observed
difference in MDR rates and they identified male gender,
chronic hemodialysis and nursing home residence as risk
factors [14].
We identified several risk factors for UTI with non-
susceptible pathogens in our study. They are similar to
those previous identified risk factors such as prior
hospitalization within 30 days, residence in nursing
homes, recurrent UTI, male gender, renal transplant-
ation, permanently indwelling urinary catheter and prior
usage of antibiotics within the last 30 days. Our analysis
considered several antibiotics and demonstrates that not
all risk factors are associated with non-susceptibility to
all antimicrobial categories. For example, residing in a
nursing home was the only significant risk factor for in-
fection with MDR pathogens, whereas hospitalization
within 30 days and indwelling urinary catheter were
significant for Ciprofloxacin resistance. This seems con-
sistent with published data that showed various risk
factors associated with different antimicrobial categories
in different studies [3, 13, 15]. A large multicenter, pro-
spective study would be necessary to further explore,
which risk factors cause non-susceptibility to certain
antimicrobial categories.
Stratification of empiric antibiotic therapy by risk
factors can improve pathogen coverage significantly. In
our study, susceptibility to standard antibiotics was over-
all less than 85%. However, when analyzed by presence
of risk factors our data showed that patients with no risk
factors had > 85% susceptibility for all standard antibi-
otics. Patients with one risk factor present had still a
susceptibility rate of 77.5 to 82.5% for cephalosporins
and 80.0% for Pip/taz. Patients with two or more risk
factors remained only susceptible to Imipenem, but its
susceptibility for Pip/taz, Gentamicin and Ceftazidime
was reasonable with 75.0% or 76.8%, respectively.
Interestingly, in our study antibiotic use within the last
30 days was associated with a higher resistance rate in
cephalosporins and Ciprofloxacin compared to the beta-
lactam penicillin Pip/taz consisted with observations that
cephalosporins and fluoroquinolones may increase the
resistance rates of bacteria [16]. Our data suggest that
patients with previous antibiotic therapy may be better
treated with Pip/taz empirically although the number of
patients in this sub-analysis was low in order to draw a
statistical sound conclusion.
There are several important limitations to consider in
our study. It was a single-center, retrospective data ana-
lysis, which depended on the accuracy of history taking
by the health care provider on call. Certain published
risk factors, such as employment in health care,
Fig. 2 Therapy algorithm for our emergency department - First-line
therapy based on susceptibility rates for patients with zero risk fac-
tors (left) and patients with one or more risk factors (right)
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exposure to farming, family members with multidrug re-
sistant pathogens, ambulant chemotherapy and wound
care, had to be excluded from our study as they have
not been recorded consistently in all cases. A selection
bias towards antibiotic resistance cannot be excluded as
not all patients presenting with UTI received a urine
culture or had a positive urine culture result. Overall,
the rate of antibiotic resistance or MDR pathogens was
high compared to similar studies.
However, our results are among the first to show risk
factors for antibiotic resistances and MDR pathogens in
UTI patients in Germany. In contrast to most studies,
we analyzed patients admitted to an emergency depart-
ment in a large tertiary care hospital and did not solely
focus on a single antibiotic substance or on MDR patho-
gens. Our results show that implementation of risk
factors can lead to significant improvement in suscepti-
bility in empirical therapy.
Our study revealed also another important aspect as
patients diagnosed with upper UTI in the ED were
admitted to the ward with an empiric antibiotic therapy,
but the sampling of urine cultures was often referred to
the ward nursing team due to logistical reasons. This led
to a high number of negative urine cultures as the anti-
biotic treatment was applied before urine cultures were
taken. Studies like these can help not only to identify
local resistant patterns or risk factors for resistant bac-
teria, it also helped us to identify serious organizational
problems in the daily routine.
Current treatment guidelines often recommend fluoro-
quinolones and cephalosporins as treatment options in
uncomplicated upper UTI. Both antimicrobial categories
should be viewed critical, because they lead to a significant
increase of Clostridium difficile colitis and may further in-
crease the rate to MDR pathogens [16, 17]. Piperacillin/
Tazobactam is less prone to induce antibiotic resistance
[18]. It also inhibits C. difficile colonization during therapy
[19]. In this regard, Pip/Taz is the better antibiotic choice.
Gentamicin can cause severe side effects, such as kidney
and inner ear damage and needs extended monitoring in
comparison to other antibiotics especially in elderly pa-
tients. Therefore, in our institution we do not recommend
Gentamicin for empiric therapy in upper UTI infections.
β-Lactamase inhibitors (BLIs) such as Tazobactam play
an important role in overcoming β-lactam resistance in
Gram-negative bacteria. Because of the emergence of
varieties of β-lactamases, their effectiveness has dimin-
ished over time. New BLI combinations with broad-
spectrum antibiotics are promising for increasing the
effectiveness of empiric antibiotic therapy in UTI [20].
Ceftolozane/tazobactam and ceftazidime/avibactam have
been approved for UTI treatment and increase the over-
all susceptibility to gram-negative bacteria. In particular,
ceftazidime/avibactam has been shown to be effective in
isolates from UTI patients resistant to Pip/Taz, Cephalo-
sporins and Carbapenems [21, 22]. In our study, bacteria
were not routinely tested for these new ß-lactamase in-
hibitor combinations as they are regarded as last line
therapies in severely ill patients due to highly resistant
bacteria.
In our setting, all standard antibiotics had a relatively
low overall susceptibility. A simple risk factor based
treatment algorithm using cephalosporins in patients
without risk factors and Pip/taz in all other patients
except for patients residing in nursing homes with
recent hospitalization in the previous 30 days increases
the antibiotic coverage rate to 86.1%. It can be debated
whether the use of Pip/taz in all cases as a broad-
spectrum beta-lactam penicillin derivative with an over-
all susceptibility rate of 80.3% would be much different
in its clinical outcome. With its advantages regarding C.
difficile colonization and induction of resistances Pip/taz
could be the better choice compared to cephalosporins
and fluoroquinolones for urinary tract infections.
Conclusions
We retrospectively identified seven independent risk fac-
tors for antimicrobial resistances in UTI patients in the
local emergency department: prior hospitalization within
30 days, residence in nursing homes, recurrent UTI, male
gender, renal transplantation, permanently indwelling
urinary catheter and prior usage of antibiotics within the
last 30 days. Antibiotic susceptibility changes significantly
in regard to risk factors present in a patient population.
These results can be used to improve empirical antibiotic
therapy in emergency departments with high rates of re-
sistances. The beta-lactam penicillin-derivate piperacillin/
tazobactam is likely the better choice compared to fluoro-
quinolones and cephalosporins as susceptibility in patients
with risk factors is comparable or better. Whether the
incidence of C. difficile colitis and the increase of multi-re-
sistant bacteria can be reduced by treatment with pipera-
cillin/tazobactam should be explored in further
randomized, prospective multi-center studies. We encour-
age readers to monitor their local susceptibility rates to
choose appropriate empirical therapy, as the local situ-
ation may significantly differ from guideline and literature
results.
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